The utility of tumor-specifically internalizing peptides for targeted siRNA delivery into human solid tumors

Frank Un, Bingsen Zhou, Yun Yen

研究成果: 雜誌貢獻文章同行評審

6 引文 斯高帕斯(Scopus)

摘要

Background: Ribonucleotide reductase composed of the hRRM1 and hRRM2 subunits catalyzes the conversion of ribonucleotides to their corresponding deoxy forms for DNA replication. Anti-hRRM2 siRNA degrades hRRM2 ' s mRNA and suppresses tumorigenesis. A Phase I clinical trial demonstrated its therapy potential. HN-1 represents a tumorspecifically internalizing peptide for targeted-drug delivery into human head and neck squamous cell carcinoma. Materials and Methods: Internalization of peptide was monitored by fluorescence microscopy. The peptide-siRNA conjugate was chemically synthesized. The hRRM2 expression was monitored by western blot analysis. Results: HN-1TYR (HN-1 with two N-terminally added tyrosines) was internalized by human head and neck or breast cancer cells. Anti-hRRM2 siRNAR (resistant to RNase degradation) was conjugated to HN-1TYR without compromising their properties. The treatment with HN-1TYR-anti-hRRM2 siRNAR partly suppressed the endogenously expressed hRRM2 in human breast cancer cells. Conclusion: Our results establish the utility of tumor-specifically internalizing peptides for targeted siRNA delivery into human cancer cells.

原文英語
頁(從 - 到)4685-4690
頁數6
期刊Anticancer Research
32
發行號11
出版狀態已發佈 - 十一月 1 2012
對外發佈

ASJC Scopus subject areas

  • 腫瘤科
  • 癌症研究

指紋

深入研究「The utility of tumor-specifically internalizing peptides for targeted siRNA delivery into human solid tumors」主題。共同形成了獨特的指紋。

引用此